Prednisone

Generic Name: Prednisone

Brand Names: Deltasone, Rayos, Winpred

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₆O_₅

CAS Number: 53-03-2

Unique Ingredient Identifier: VB0R961HZT

Background: A synthetic anti-inflammatory glucocorticoid derived from cortisone. It is biologically inert and converted to prednisolone in the liver.

Prednisone was granted FDA approval on 21 February 1955.

Indication: Prednisone is indicated as an anti-inflammatory or immunosuppressive drug for allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, infectious, endocrine, or neoplastic conditions as well as in organ transplant.

Associated Conditions: Acne Vulgaris, Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Acute Gouty Arthritis, Acute Leukemia, Aggressive Lymphoma, Allergic Bronchopulmonary Aspergillosis, Allergic Conjunctivitis (AC), Allergic Rhinitis (AR), Allergic corneal marginal ulcers, Alveolitis, Extrinsic Allergic, Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Autoimmune Hepatitis, Bell's Palsy, Berylliosis, Bullous dermatitis herpetiformis, Chorioretinitis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Contact Dermatitis, Disseminated tuberculosis, Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Erythroblastopenia, Giant Cell Arteritis (GCA), Hypercalcemia of Malignancy, Idiopathic Pulmonary Fibrosis (IPF), Immune Thrombocytopenia (ITP), Iridocyclitis, Iritis, Keratitis, Leukemias, Loeffler's syndrome, Lymphoma, Meningitis caused by Mycobacterium Tuberculosis, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Mycosis Fungoides (MF), Ocular Inflammation, Ophthalmia, Sympathetic, Optic Neuritis, Pain caused by Herpes zoster, Pemphigus, Pericarditis, Pneumocystis Jirovecii Pneumonia, Polymyalgia Rheumatica (PMR), Polymyositis, Posterior Uveitis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Regional Enteritis, Relapsing Polychondritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Sjogren's Syndrome (SS), Solid Organ Transplant Rejection, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Thyroid Eye Disease, Thyroiditis, Thyrotoxicosis, Trichinosis, Ulcerative Colitis, Uveitis, Vasculitis, Acquired immune hemolytic anemia, Acute Bursitis, Acute Crohn's Disease (CD), Acute Multiple sclerosis exacerbation, Acute rheumatic carditis, Anterior eye segment inflammation, Exfoliative erythroderma, Fulminating Tuberculosis, Idiopathic Bronchiolitis obliterans with organizing pneumonia, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Psoriasis, Subacute Bursitis, Symptomatic Sarcoidosis, Synovitis of osteoarthritis, Systemic Dermatomyositis, Varicella-zoster virus acute retinal necrosis

Associated Therapies: Palliative Treatment

Clinical Trials

Short-course High-dose Prednisone and Dexamethasone in Children With ITP

Phase 4

Recruiting

Conditions: Child, Only
Immune Thrombocytopenia
Glucocorticoids

Interventions: Drug: Prednisone
Drug: Dexamethasone

First Posted Date: 2022-08-31

Last Posted Date: 2024-05-16

Lead Sponsor: Fujian Medical University Union Hospital

Target Recruit Count: 608

Registration Number: NCT05522465

Locations: 🇨🇳
Children with newly dignosed ITP, Fujian, Fujian, China

A Study of Olverembatinib in the Treatment of Ph+ ALL

Phase 2

Not yet recruiting

Conditions: Philadelphia-Positive ALL

Interventions: Drug: Olverembatinib
Drug: Prednisone
Drug: Vincristine

First Posted Date: 2022-07-20

Last Posted Date: 2022-09-01

Lead Sponsor: Chen Suning

Target Recruit Count: 55

Registration Number: NCT05466175

Locations: 🇨🇳
The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Suzhou, Jiangsu, China

Combined Steroid and Cyclosporin as First-line Treatment in Adults With Primary Immune Thrombocytopenia

Phase 2

Not yet recruiting

Conditions: Immune Thrombocytopenia

Interventions: Drug: Cyclosporine Oral Product
Drug: Prednisone

First Posted Date: 2022-07-15

Last Posted Date: 2022-07-15

Lead Sponsor: Peking University People's Hospital

Target Recruit Count: 253

Registration Number: NCT05459649

Locations: 🇨🇳
Peking University Insititute of Hematology, Peking University People's Hospital, Beijing, Beijing, China

Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma

Phase 1

Recruiting

Conditions: Diffuse Large B-Cell Lymphoma
Grade 3b Follicular Lymphoma
High Grade B-Cell Lymphoma

Interventions: Procedure: Bone Marrow Biopsy
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Prednisone
Biological: Retifanlimab
Biological: Rituximab and Hyaluronidase Human
Biological: Tafasitamab
Drug: Vincristine
Procedure: Bone Marrow Aspiration
Procedure: Multigated Acquisition Scan
Other: Fludeoxyglucose F-18
Procedure: Positron Emission Tomography
Procedure: Computed Tomography
Procedure: Biospecimen Collection
Drug: Polatuzumab Vedotin

First Posted Date: 2022-07-13

Last Posted Date: 2024-11-20

Lead Sponsor: University of Washington

Target Recruit Count: 35

Registration Number: NCT05455697

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations

Phase 4

Active, not recruiting

Conditions: Metastatic Castration-resistant Prostate Cancer

Interventions: Drug: olaparib
Drug: enzalutamide
Drug: abiraterone acetate
Drug: Prednisone

First Posted Date: 2022-07-13

Last Posted Date: 2024-11-11

Lead Sponsor: AstraZeneca

Target Recruit Count: 43

Registration Number: NCT05457257

Locations: 🇨🇳
Research Site, Zhengzhou, China

Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia

Phase 2

Recruiting

Conditions: B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative

Interventions: Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Etoposide
Drug: Prednisone
Biological: Rituximab
Biological: Tafasitamab
Drug: Vincristine
Procedure: Bone Marrow Aspiration
Procedure: Bone Marrow Biopsy
Procedure: Computed Tomography
Procedure: Lumbar Puncture
Procedure: Biospecimen Collection

First Posted Date: 2022-07-12

Last Posted Date: 2024-04-23

Lead Sponsor: University of Washington

Target Recruit Count: 30

Registration Number: NCT05453500

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Early Discontinuation of Steroid Treatment in Negative FDG-PET/CT Patients With Idiopathic Retroperitoneal Fibrosis

Phase 4

Recruiting

Conditions: Idiopathic Retroperitoneal Fibrosis

Interventions: Drug: Prednisone

First Posted Date: 2022-06-23

Last Posted Date: 2024-01-25

Lead Sponsor: Assistance Publique - Hôpitaux de Paris

Target Recruit Count: 41

Registration Number: NCT05428826

Locations: 🇫🇷
Médecine interne - Delafontaine, Saint-Denis, France
🇫🇷
Médecine interne - Saint Antoine, Paris, France
🇫🇷
Médecine Interne, Vascularites et Myosites - La Pitié Salpêtrière, Paris, France

and more 12 locations

Selinexor Plus R-CHOP in High-risk GCB-subtype Diffuse Large B-Cell Lymphoma

Phase 2

Recruiting

Conditions: DLBCL Germinal Center B-Cell Type

Interventions: Drug: Selinexor
Drug: Rituximab
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Vincristine
Drug: Prednisone

First Posted Date: 2022-06-16

Last Posted Date: 2024-06-17

Lead Sponsor: Li Zhiming

Target Recruit Count: 50

Registration Number: NCT05422066

Locations: 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
🇨🇳
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
🇨🇳
Hubei Cancer Hospital, Wuhan, Hubei, China

and more 3 locations

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007)

Phase 2

Active, not recruiting

Conditions: Lymphoma, Large B-Cell, Diffuse (DLBCL)

Interventions: Biological: Zilovertamab Vedotin
Drug: Cyclophosphamide
Drug: Doxorubicin
Biological: Rituximab
Biological: Rituximab Biosimilar
Drug: Prednisone
Drug: Prednisolone

First Posted Date: 2022-06-06

Last Posted Date: 2024-10-14

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 60

Registration Number: NCT05406401

Locations: 🇰🇷
Seoul National University Hospital ( Site 0201), Seoul, Korea, Republic of
🇰🇷
Samsung Medical Center ( Site 0200), Seoul, Korea, Republic of
🇨🇦
BC Cancer Victoria-Clinical Trials Unit ( Site 0105), Victoria, British Columbia, Canada

and more 19 locations

Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas

Phase 1

Suspended

Conditions: Diffuse Large Cell Lymphoma
Non-Hodgkin Lymphoma
Burkitt Lymphoma
Plasmablastic Lymphoma
B-Cell Neoplasm

Interventions: Drug: Vincristine
Drug: Prednisone
Drug: Doxorubicin
Drug: Etoposide
Drug: Pomalidomide
Drug: Cyclophosphamide
Drug: Rituximab

First Posted Date: 2022-05-25

Last Posted Date: 2024-11-27

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 20

Registration Number: NCT05389423

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy